Sutro Biopharma Financials

Sutro Biopharma (STRO) reported $102.5M in total revenue for fiscal year 2025. This represents a 65.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Sutro Biopharma (STRO) revenue grew by 65.2% year-over-year, from $62.0M to $102.5M in fiscal year 2025.

No, Sutro Biopharma (STRO) reported a net income of -$191.1M in fiscal year 2025, with a net profit margin of -186.5%.

Sutro Biopharma (STRO) reported diluted earnings per share of $-22.49 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sutro Biopharma (STRO) had EBITDA of -$151.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Sutro Biopharma (STRO) had an operating margin of -154.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Sutro Biopharma (STRO) had a net profit margin of -186.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Sutro Biopharma (STRO) generated -$177.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Sutro Biopharma (STRO) had $173.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Sutro Biopharma (STRO) invested $166.4M in research and development during fiscal year 2025.

Sutro Biopharma (STRO) had 17M shares outstanding as of fiscal year 2025.

Sutro Biopharma (STRO) had a current ratio of 2.01 as of fiscal year 2025, which is generally considered healthy.

Sutro Biopharma (STRO) had a debt-to-equity ratio of -2.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Sutro Biopharma (STRO) had a return on assets of -109.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Sutro Biopharma (STRO) had $58.1M in cash against an annual operating cash burn of $177.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Sutro Biopharma (STRO) has negative shareholder equity of -$132.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Sutro Biopharma (STRO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Sutro Biopharma (STRO) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.